Head-to-head evidence
GS101 vs Rademikibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline
GS101
Developed by Jiangsu Genscend Biopharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT07386743 (registry estimate)
Rademikibart
Developed by Simcere Pharmaceutical and partners
NCT05017480 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 330 participants, with a clinical primary endpoint based on validated Investigator Global Assessment. Although the reported primary response favored rademikibart (29.0% vs 5.9%), the registry does not state whether the primary comparison was statistically significant, so the result remains unclear.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GS101's landscape · Rademikibart's landscape